• DOI:10.1080/00016480601110212
• Corpus ID: 25519271

Intratympanic treatment of acute acoustic trauma with a cell-permeable JNK ligand: a prospective randomized phase I/II study

@article{Suckfuell2007IntratympanicTO,
  title={Intratympanic treatment of acute acoustic trauma with a cell-permeable JNK ligand: a prospective randomized phase I/II study},
  author={>M. Suckfuell and Martin Canis and Sebastian Strieth and Hans H. Scherer and Andreas Haisch},
  journal={Acta Oto-Laryngologica},
  year={2007},
  volume={127},
  pages={938 - 942}
}

• >M. Suckfuell, M. Canis, +2 authors A. Haisch
• Published 1 January 2007
• Medicine
• Acta Oto-Laryngologica

Objectives. Intratympanic administration of a cell-permeable JNK ligand has been shown to prevent hearing loss after acute acoustic trauma in animal models. Conclusions. Functional and morphological analysis of the treated ears revealed that AM-111 had an excellent otoprotective effect, even when administered hours after the noise exposure. Blocking the signal pathway with D-JNKI-1 is therefore a promising way to protect the morphological integrity and physiological function of the inner ear in various conditions involving acute sensorineural hearing loss. Subjects and methods. For the first application of AM-111 in humans, we organized a clinical phase I/II trial in patients with acute acoustic trauma after exposure to firecrackers in Berlin and Munich on New Year's Eve 2005/2006. We randomly selected 11 patients for intratympanic treatment with AM-111 at a concentration of 0.4 mg/ml or 2 mg/ml within 24 h after noise exposure. Pure tone audiometry and otoacoustic emissions were assessed before treatment and on days 3 and 30 thereafter. Results. Based on clinical experience and on a calculation using an empirically derived exponential hearing recovery function AM-111 seems to have had a therapeutic effect. A total of 13 adverse events were reported in 5 study participants. None of the adverse events were serious or severe.